menu
    • menu
    [{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD30 CAR-T","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD30 CAR-T Cell","moa":"CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CD30 CAR-T Cell","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Series A Financing","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Bendamustine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD30","graph1":"Oncology","graph2":"Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2022","type":"Agreement","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Tessa Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||Lymphocyte activation antigen CD30 (TNFRSF8)","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessa Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Autologous Ebv Cytotoxic T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tessa Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Tessa Therapeutics

    Menu

    Tessa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11X,Fludarabine Phosphate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd Line Hod...

                            Details : TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 16, 2023

                            Lead Product(s) : TT11X,Fludarabine Phosphate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National C...

                            Details : Under terms of the CRADA, Tessa will collaborate with the NCI’s DCTD to identify potential opportunities to expand the applicability of TT11X, Tessa’s allogeneic off-the-shelf CD30.CAR-modified EBVST cell therapy, as a treatment of non-Hodgkin lympho...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30...

                            Details : The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 12, 2022

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Baylor College of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Sh...

                            Details : TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            November 07, 2022

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Baylor College of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Pro...

                            Details : TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : TT11X

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11,Fludarabine Phosphate,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivol...

                            Details : TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 17, 2022

                            Lead Product(s) : TT11,Fludarabine Phosphate,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS C...

                            Details : TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 13, 2022

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Polaris Partners

                            Deal Size : $126.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners

                            Details : Tessa plans to use the proceeds from the financing to advance the ongoing clinical development of the company’s autologous CD30-CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) programs.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Polaris Partners

                            Deal Size : $126.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

                            Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hodgkin Disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 29, 2022

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Tessa Therapeutics

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

                            Details : The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 18, 2021

                            Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth